Adagene vs CytomX Therapeutics
ADAG and CTMX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ADAG and CTMX compare
Adagene grew revenue faster over the last twelve months (7333% versus −87.7% for CytomX Therapeutics).
Adagene keeps more of each dollar of sales as profit, with a net margin of −230% compared with −609% at CytomX Therapeutics.
CytomX Therapeutics scores higher on the StockData Score (8 against 5 for Adagene), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ADAG | CTMX |
|---|---|---|
| Size and price | ||
| Market cap | – | $445M |
| Share price | $1.71 | $2.04 |
| Change, 1 year | −3.4% | −51.8% |
| Change, 5 years | −82.5% | −72.2% |
| Beta (5Y) | 0.73 | 1.59 |
| Employees | 128 | 69 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 31.7× |
| P/B | – | 1.6× |
| FCF yield | – | −11.5% |
| Growth | ||
| Revenue growth (TTM) | 7333% (better) | −87.7% |
| Revenue growth, 5Y average | 61.4% (better) | 2.2% |
| Net income growth (TTM) | – | −405% |
| EPS growth (TTM) | – | −215% |
| Profitability | ||
| Operating margin | −279% (better) | −676% |
| Net margin | −230% (better) | −609% |
| FCF margin | −204% (better) | −364% |
| Return on equity | −27.7% (better) | −43.6% |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.00 |
| Interest coverage | −46.3× | – |
| Current ratio | 5.02 | 7.82 (better) |
| Altman Z-score | – | 0.58 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | −55.0% |
| Shareholder yield | – | −55.0% |
| Ownership | ||
| Held by institutions | 32.5% | 97.9% |
| Held by insiders | 16.8% | 1.5% |
| Insider net buying, 12 months | $162K (better) | −$1.2M |
| Short interest, % of float | – | 21.1% |
Go deeper
- ADAG stock overview
- ADAG income statement
- ADAG valuation and score
- CTMX stock overview
- CTMX income statement
- CTMX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.